2018 HIV DIAGNOSTICS

47. Support POC EID as well as case-finding through enhanced testing in inpatient, TB, and nutrition wards.

48. Support broader uptake of new sample types for laboratory systems and multiplex testing to improve cost efficiencies.

49. Support case-finding through contact tracing and testing, including at the community level.

Updates

47. Worked with MoH in Unitaid-funded POC EID project countries to ensure transition to national management and new funding sources. Funding now secured in almost all project countries.

2020 HIV DIAGNOSTICS

13. Work with civil society, communities, governments and multilaterals to scale up access to POC EID through advocacy and technical leadership.

14. Work with governments, FBOs, and health care workers to implement evidence-based strategies for pediatric HIV case finding, especially for older children, and increase demand through community-led education to ensure that all children along the continuum of care are reached.

 

15. Optimize POC EID by promoting integrated disease testing for childhood HIV and TB on the same platform.

Updates

-

2020 TB DIAGNOSTICS

50. Through its Unitaid-funded project CAP-TB, improve pediatric TB care, finding more children with latent or active TB, and putting them on appropriate treatment. This includes improving the increased access and use of TB preventive Treatment in the high-risk population of child contacts <5 and CLHIV.

Updates

-

2020 HIV TREATMENT

56. Through the Unitaid Optimal grant, accelerating access to optimal pediatric ARVs for children, including DTG 10 mg dispersible tablets, across focal countries.

 

58. Support MOHs to accelerate the introduction and roll out of optimized formulations in at least 6 countries: Kenya, Uganda, Tanzania, Senegal, Burkina Faso and Cameroon.

59. Support health system strengthening and access to DRV and ETR as part of the New Horizons Advancing Pediatric HIV Care Collaborative (NHC) supported by J&J. This will be achieved through technical assistance in identifying and managing HIV treatment failure in children and adolescents, capacity building, evidence generation, supply chain management, and support for harmonized TB co-infection screening.

Updates

-

2017 ROME ACTION PLAN

Action 22. Support the early adoption of priority formulations and diagnostics and take steps to facilitate their wider roll-out, including by developing introductory guidance, materials, and other tools for health facilities.

Action 27: Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.

Action 27: Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.

Action 29: Promote uptake by mobilizing their networks of hospitals and community structures to distribute paediatric medicines in hard to reach places and in situations of conflict and crisis.

Action 34: Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.

Action 37. Take responsibility for monitoring implementation of the Action Plan and holding actors to account, including monthly calls of principals, tracking progress towards milestones, and regularly communicating with participants about progress on their commitments and overall implementation of the Plan.

Action 38. Develop a set of milestones in 2018 to highlight progress on the Action Plan and establish opportunities for stakeholders to take on more specific commitments.

Action 41. Organize a follow-up meeting focused on diagnostics for children in Q1 2018.

Action 22

 

GAP-f partners have been discussing with ViiV and regulatory authorities to determine the best regulatory pathways for pediatric DTG (10 mg scored and 50 mg scored tablets) and ways to accelerate registration and introduction of DTG and RAL at country level.

EGPAF and CHAI are beginning preparations for introduction of DTG and RAL (EGPAF), including production of a DTG introduction toolkit. DNDi is working with in-country partners on expand uptake of LPV/r solid formulations for the roll-out of introductory materials.

Action 37

Chairs of the AIDS free working group regularly update all stakeholders about the implementation of the action plan via email.

Notes: For updated information on communication please view update section of the website.

Project management team, active since December 2017 (WHO, EGPAF, PEPFAR, WCC-EAA).  Project management team regularly reaches to stakeholders to gain updates and promote progress on the commitments.

Notes: Sub-action completed

For regular updates see updates section in the website. First webinar took place on 24 April 15:00-16:30 CET. Second webinar scheduled to take place 17 October 14:30-15:30 CET. Regular calls of the AIDS Free working Group partners helped to advance the Action Plan and review progress.

Action 38

Set of milestones to highlight progress on the action plan, available on https://www.paediatrichivactionplan.org/. Tracker website: https://www.paediatrichivactionplan.org/. Progress Report on Implementation Rome Action Plan (June 2018) available in Updates and Library sections. First webinar scheduled took place 24 April 2018 15:00-16:30 CET. Second webinar scheduled to take place 17 October 2018 14:30-15:30 CET.

Concept Paper developed and planning ongoing.

Action 41

WHO, EGPAF, PEPFAR and WCC-Ecumenical Advocacy Alliance (WCC-EAA) have begun discussions on more additional meetings on pediatric diagnostics in Q1 and Q2 of 2018; and about a high-level dialogue on diagnostics in december 2018.

Notes: Diagnostics concept paper prepared. To be discussed amongst AIDS Free  partners.

Pre-AIDS 2018 joint meeting with manufacturers, partners, and countries. Hosted by WHO, EGPAF and AIDS Free Partners.​

Rome 4: High Level Dialogue Vatican 6-7 December 2018

2018 HIV TREATMENT

26. DNDi, ICAP, and EGPAF commit to collaborate on product uptake for solid oral dosage forms of
LPV/r (2-in-1’s and 4-in-1), including:

  • Development of healthcare workers’ training tools based on implementation research data generated by DNDi; and

  • Acceleration of product uptake in selected countries with engagement of all stakeholders including MOH, civil society, FBOs, and communities of people living with HIV, and to share the training toolkit and experience by disseminating information globally.

28. Partner on the assisted introduction of RAL granules for neonates, starting with the MoH of Eswatini, followed by other countries beginning early 2019, donating sufficient supplies at the outset of the project and then selling at no profit in low income and sub-Saharan African countries to ensure sustainability of the initiative.

Updates

Commitment 26

ICAP is developing training tools, EGPAF is reviewing and providing feedback.

With support of Unitaid and DNDi, working in 8 countries on scale-up of LPV/r 2-in-1 solid formulations and DTG 50mg and new dispersible DTG products

Commitment  28

Working with CDC, CRS, Zimbabwe MoH and Merck to introduce RAL granules for use among neonates.

Updates
2020 TB TREATMENT

109. Through its Unitaid-funded project CAP-TB, improve pediatric TB care, finding more children, and putting them in treatment, including improving the increased access and use of TB preventive Treatment in the high risk population of child contacts < 5 and CLHIV.

 

119. Advocate for and support Ministries of Health to rapidly transition to optimal paediatric formulations as outlined by the latest WHO guidelines, provide coordinated support for the development and implementation of transition plans, inform clinicians and patients of the value of transitioning to new formulations, and ensure communication of reliable information on the availability of new formulations in-country.

 

120. Support the scale up of access to priority formulations and diagnostics and take steps to facilitate their wider roll-out, including by performing operational research, developing introductory guidance and education, materials, and other tools for health facilities and local community health structures.

121. Promote the revision of national procurement plans to align with WHO recommended regimens and the EML-C, and support the provision of reliable forecasts and the consolidation of orders.

 

122. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to TB diagnosis and treatment among children in close collaboration with other stakeholders.

123. Raise awareness in local, national, and global fora about the unmet diagnostic and treatment and prevention needs of children with or at risk for TB.

124. Foster and more actively participate in coordinated and collaborative advocacy to:

  • Increase funding for TB research & development, introduction and scale-up of priority paediatric drugs and formulations; 

  • Accelerate regulatory processes for rapid adoption and uptake of optimal paediatric TB drugs and formulations; and

  • Ensure sustainable access to optimal TB testing and treatment for infants and children.

 

125. Tackle the TB stigma and discrimination in communities, schools, and healthcare settings that prevent children and adolescents living with TB or at risk of TB from accessing testing and treatment, including promotion of awareness of the difference between infection and disease  and include messages of hope regarding treatment of both HIV and TB.

 

126. Promote uptake by mobilizing their networks of hospitals and community structures to distribute paediatric medicines in hard to reach places and in situations of conflict and crisis.

Updates

-